

2nd World Congress of

World Association on Dual Disorders



Dual Disorders: Towards a New Paradigm in Neuroscience to Understand Mental Health

25-27 October 2018
Convitto della Calza
Florence, Italy, EU



WADD
World Association
on Dual Disorders



WADD
World Association
on Dual Disorders



WADD
World Association
on Dual Disorders



WADD
World Association
on Dual Disorders



WADD
World Association
on Dual Disorders

WADD

WORLD ASSOCIATION ON DUAL DISORDER

WADD was founded in Barcelona (Spain) in April 2015. It shall remain independent of political parties and of any government.

The vision

The World Association of Dual Disorders (WADD) was created to

- Increase the level of knowledge and education on Dual Disorders
- Create a live tool which can serve as the major point of reference and contact to Dual Disorders related professionals.
- Increase the awareness of Dual Disorders worldwide and offer a platform for all Dual Disorder professionals.
- Promote the research on Dual Disorders.
- Promote the dissemination of information on Dual Disorders among health professionals, government and the public at large.
- Give voice to and represent professionals in the Dual Disorder area by providing information and scientific knowledge.
- Reduce the stigma related to Dual Disorders

WADD Executive Committee

Pedro Ruiz (Houston, TX, USA) - President
Miguel Casas (Barcelona, Spain, EU) - Vice President
Nestor Szerman (Madrid, Spain, EU) - Executive Secretary
Icro Maremmani (Pisa, Italy, EU) - Treasurer



WADD
World Association
on Dual Disorders

WADD-Italia Scientific Committee

Giampaolo Spinnato (Palermo, Italy, EU) - President
Icro Maremmani (Pisa, Italy, EU) - Scientific Director
Vinicio Claudio Romano (Piazza Armerina, Italy, EU) - Member
Riccardo Gionfriddo (Siracusa, Italy, EU) - Member
Francesco Lamanna (Pisa, Italy, EU) - Member



WADD
World Association
on Dual Disorders

Italian Scientific Committee



Under the Patronage of

WADD - World Association on Dual Disorder

WADD-Italia Scientific Committee

Promoted by

WADD-Italia Scientific Committee

Association for the Application of Neuroscientific Knowledge to Social Aims

Congress Presidents

PEDRO RUIZ (Houston, TX, USA)

ICRO MAREMMANI (Pisa, Italy, EU)

Local Scientific Committee

GIULIO PERUGI (Pisa, Italy, EU)

GIAMPAOLO SPINNATO (Palermo, Italy, EU)

Venue

Convitto della Calza

Piazza della Calza, 6

50125 Florence FI

Phone: +39 055 22228

E-mail: CALZA@CALZA.IT

Website: <https://www.calza.it/en>

Organizing Committee

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy


Phone +39 0564412038 - Fax +39 0564412485

E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy

Phone +39 0584790073 - Fax +39 058472081

E-mail: info@aucns.org



PROGRAM

THURSDAY, OCTOBER 25, 2018

WADD SELECTED ORAL PRESENTATIONS

Plenary Room	ABSTRACT No	WADD Selected Presentations <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
8:20	SOP-1	DANIEL FEINGOLD (Ariel, Israel) - Clinical and functional outcomes of cannabis use among individuals with depression and anxiety: a three-year population-based longitudinal study
8:40	SOP-2	NADIR BOURBON (Blida, Algeria) - Opiate addiction and others psychiatric diagnosis
9:00	SOP-3	EMANUELA ATZORI (Roma, Italy, EU) - The alteration of the sensory consciousness of the SELF as a trigger mechanism determining a craving in gambling and eating disorders. A pilot study
9:20	SOP-4	LEE KUN-HUA (Hsinchu, Taiwan) - The training and recruits of mindfulness-based relapse prevention therapist in Taiwan: a descriptive study
9:40	SOP-5	SHAUL LEV-RAN (Netanya, Israel) - Comparing substance misuse, anxiety and depression among individuals with chronic pain receiving prescription opioids and medical marijuana
10:00	SOP-6	FRANCINA FONSECA (Barcelona, Spain, EU) - Personality traits, psychiatric comorbidity and methadone maintenance treatment outcome
10:20	SOP-7	MYRIAM PAPERMAN (Paris, France, EU) - Borderline Personality Disorder and Substance Use Disorder: A life worth living?
10:40	WADD General Assembly	
11:40	SPECIAL EVENT in collaboration with Industry	

THURSDAY, OCTOBER 25, 2018

Plenary Room	ABSTRACT No	
		OPENING CEREMONY PEDRO RUIZ (Houston, TX, USA) MIGUEL CASAS (Barcelona, Spain, EU) NESTOR SZERMAN (Madrid, Spain, EU) ICRO MAREMMANI (Pisa, Italy, EU)
		PLENARY LECTURES <i>Chair: Icro Maremmanni (Pisa, Italy, EU)</i> <i>Miguel Casas (Barcelona, Spain, EU)</i>
13:30	PL-1	PEDRO RUIZ (Houston, TX, USA) - Focus on Dual Disorder
14:30	PL-2	MICHAEL KRAUSZ (Vancouver, BC, Canada) - Homeless and hopeless – marginalized urban with complex concurrent disorders and the North American overdose crisis
		PARALLEL SYMPOSIA
Plenary Room	ABSTRACT No	1- SOUTH EASTERN EUROPEAN ADDICTION TREATMENT NETWORK (SEANET) SYMPOSIUM- PART 1 <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
15:30	S01-1	LILJLANA IGNJATOVA (Skopje, North Macedonia) - Differences and similarities in opioid use and bipolar disorders
16:00	S01-1	NUSA SEGREC (Ljubljana, Slovenia, EU) - Sexual dysfunction among men in agonist opioid treatment
16:30	S01-1	JELEANA RISTIC-ILIC (Ljubljana, Slovenia, EU) - Personality disorders and substance abuse
Room A		2- IMPROVING TREATMENT OUTCOMES IN DUAL DISORDER PATIENTS: AN OVERVIEW OF NEW PSYCHOLOGICAL AND BEHAVIOURAL INTERVENTIONS IN CLINICAL PRACTICE <i>Chair: Tony Bloemendaal (Den Haag, Nederland, EU)</i>
15:30	S02-1	ANNETTE BONEBAKKER (Den Haag, Netherlands, EU) - New perspectives on the treatment of duals disorders: integrative care and psychological treatments
16:00	S02-2	ERNST NOORDRAVEN (Den Haag, Netherlands, EU) - Money for medication: financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders; a randomised controlled trial
16:30	S02-3	TONY BLOEMENDAAL (Den Haag, Netherlands, EU) - Treatment no-response in patients with a dual disorder
Room B		3-DUAL DISORDER PATIENTS IN COMMUNITY MENTAL HEALTH SERVICES <i>Chair: Celia Franco (Coimbra, Portugal, EU)</i>
15:30	S03-1	TANIA SILVA (Coimbra, Portugal, EU) - Dual disorder patient in community mental health services: the experience of the centre of Portugal
16:00	S03-2	FILOMENA NETO (Coimbra, Portugal, EU) - Dual disorder patient: multidisciplinary team intervention in community mental health services
16:30	S03-3	CELIA FRANCO (Coimbra, Portugal, EU) - Treating addiction patients in community mental health services: the role of opioid treatment
		PLENARY LECTURE <i>Chair: Gabriele Fischer (Vienna, Austria, EU)</i> <i>Arturo Lerner (Tel Aviv, Israel)</i>
18:00	PL-3	NESTOR SZERMAN (Madrid, Spain, EU) - Precision Medicine in Dual Disorders
19:00	PL-4	MIGUEL CASAS (Barcelona, Spain, EU) - Cocaine Addiction: a self-medication hypothesis. A systematic review
20:00		WELCOME COCKTAIL AND LUCA ROVAI RESEARCH AWARD

Plenary Room ABSTRACT No

FRIDAY, OCTOBER 26, 2018

PARALLEL SYMPOSIA

		4 - DUAL DISORDERS TREATMENT <i>Chair: Vera Martins (Coimbra, Portugal, EU)</i>
9:00	S04-1	CELIA FRANCO (Coimbra, Portugal, EU) - Treatment phases in dual patients
9:30	S04-2	ELISABETE ALBUQUERQUE (Coimbra, Portugal, EU) - Opioid treatment: a new way to understand addiction
10:00	S04-3	VERA MARTINS (Coimbra, Portugal, EU) - The role of treatment in day hospital in dual disorders patients
Room A		5- ARE BENZODIAZEPINES THE CURE FOR OR THE CAUSE OF PROBLEMS? THE ROLE OF BENZODIAZEPINES IN TREATMENT AND OUTCOMES OF OPIOID ADDICTION <i>Chair: Thomas Clausen (Oslo, Norway)</i>
9:00	S05-1	LARS TANUM (Oslo, Norway) - Use of benzodiazepines among opioid dependent individuals during a 12 week randomised study and a 36-week follow-up study with extended release naltrexone
9:30	S05-2	ASHLEY MULLER (Oslo, Norway) - Long-term opioid maintenance treatment patients and the role of benzodiazepines
10:00	S05-3	THOMAS CLAUSEN (Oslo, Norway) - Unprescribed benzodiazepine use predicts one-year instability in opioid maintenance treatment
Room B		6- OUTCOME OF PATIENTS WITH DUAL DIAGNOSIS - EXPERIENCE OF 25 YEARS IN METHADONE MAINTENANCE TREATMENT CLINIC <i>Chair: Einat Peles (Tel Aviv, Israel)</i>
9:00	S06-1	EINAT PELES (Tel Aviv, Israel) - Predictors for schizophrenia and psychotic patients outcome in methadone maintenance treatment
9:30	S06-2	ANAT SASON (Tel Aviv, Israel) - Depression, food addiction, weight gain and nutrition habit among patients in methadone maintenance treatment
10:00	S06-3	SHAUL SCHREIBER (Tel Aviv, Israel) - The relation between brief psychiatric rating scale (BPRS) on admission to methadone maintenance treatment and treatment outcome
10:30		BREAK
		PLENARY LECTURES <i>Chair: Giulio Perugi (Pisa, Italy, EU)</i> <i>Nestor Szerman (Madrid, Spain, EU)</i>
11:00	PL-5	MARIO MAJ (Naples, Italy, EU) - The clinical, etiopathogenetic and therapeutic complexity of schizophrenia
12:00	PL-6	ICRO MAREMMANI (Pisa, Italy) - Clinical foundation for the use of Agonist Opioid Medications in Bipolar Disorder and Psychosis
13:15		LUNCH BREAK

Plenary Room	ABSTRACT No	
PLENARY LECTURES		
<i>Chair: Icro Maremmanni (Pisa, Italy, EU) Christian Schutz (Vancouver, Canada)</i>		
14:30	PL-7	GIULIO PERUGI (Pisa, Italy, EU) - Aetiopathogenetic and Therapeutic Complexity of Bipolar Disorders
15:30	PL-8	MARTA TORRENS (Barcelona, Spain, EU) - Opioid and depression
PARALLEL SYMPOSIA		
Plenary Room	ABSTRACT No	7- SUBSTANCE USE DISORDERS AND PSYCHIATRIC COMORBIDITIES: WHICH TREATMENT OPTIONS DO WE HAVE? <i>Chair: Marta Torrens (Barcelona, Spain, EU)</i>
16:30	S07-1	ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Substance abuse and psychosis: the strange case of opioids
17:00	S07-2	CARLO IGNAZIO CATTANEO (Borgonero, Italy, EU) - The phenomenon of drug resistance in substance induced psychosis
17:30	S07-3	CORRADO MANNI (Pisa, Italy, EU) - Cocaine use disorder in ADHD individuals: focus on comorbidities and treatments outcome
Room A		8- DUAL DISORDERS IN MEXICO <i>Chair: Carmen Fernandez Caceres (Mexico City, Mexico)</i>
16:30	S08-1	CARMEN FERNANDEZ CACERES (Mexico City, Mexico) - Dual disorders in drug users served in a network of specialized addiction care
17:00	S08-2	ANGEL PRADO GARCIA (Mexico City, Mexico) - From prevention to rehabilitation, a continuum under the dual pathology model
17:30	S08-3	ANDREA GALLEGOS-CARI (Mexico City, Mexico) - Electronic screening tool for dual disorders in residential facilities to treat SUDs in Mexico City
Room B		9-COMORBIDITY AND SEXUALLY TRANSMITTED INFECTIONS – LONGITUDINAL EVIDENCE, TREATMENT SEEKING AND TREATMENT OPPORTUNITIES <i>Chair: Rosa Alati (Brisbane, Australia)</i>
16:30	S09-1	ROSA ALATI (Brisbane, Australia) - Generational changes in substance use – cross country comparisons
17:00	S09-2	CAROLINE SALOM (Brisbane, Australia) - Longitudinal links between comorbidity, treatment-seeking and sexually transmitted infections – opportunities for screening and treatment
17:30	S09-3	RODRIGO MARIN-NAVARRETE (Mexico City, Mexico) - Development of an evidence-based model of rapid testing and counselling for HIV and other ITDs for addiction treatment centres in Mexico
PLENARY LECTURES		
<i>Chair: Michael Krausz (Vancouver, BC, Canada) Yifrah Kaminer (Hartford, CT, USA)</i>		
18:00	PL-9	CHRISTIAN G. SCHÜTZ (Vancouver, Canada) - Disentangling dual diagnosis: focus on stimulants and psychotic disorders

Plenary Room	ABSTRACT No
SATURDAY, OCTOBER 27, 2018	
PARALLEL SYMPOSIA	
	10 - SOUTH EASTERN EUROPEAN ADDICTION TREATMENT NETWORK (SEANET) SYMPOSIUM- PART 2 <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
9:00	S10-1 MIRJANA DELIC (Ljubljana, Slovenia, EU) - Use of psychedelics and antagonists in psychiatric treatment: pros and cons
9:30	S10-2 TATJA KOSTNAPFEL (Ljubljana, Slovenia, EU) - Outpatient prescription of antidepressants and anxiolytics in Slovenia
10:00	S10-3 MARJETKA JELENC (Ljubljana, Slovenia, EU) - Zolpidem use in elderly patients in Slovenia
Room A	11- PSYCHO-ADDICTOLOGY: FROM CONCEPTUALIZATION TO APPLICATION <i>Chair: Amine Benyamina (Paris, France, EU)</i>
9:00	S11-1 DANIELE ZULLINO (Geneve, Switzerland) - The institutionalization of psycho-addictology in Switzerland: the federal diploma of advanced training
9:30	S11-2 GEORGES BROUSSE (Clermont Ferrand, France, EU) - The dimensional approach in the service of psycho-addictology: the example of impulsivity
10:00	S11-3 ISMAIL RAMMOUZ (Agadir, Morocco) - Towards a psychopharmacology with dual action?
Room B	12- HOT TOPICS IN DUAL DISORDERS <i>Chair: Roger D. Weiss (Boston, MA, USA)</i>
9:00	S12-1 ALBRECHT ULMER (Stuttgart, Germany, EU) - Medical adjustment of alcohol dependence with baclofen, dihydrocodeine, buprenorphine, clomethiazole and possible other substances
9:30	S12-2 MATTEO PACINI (Pisa, Italy, EU) - Benzodiazepine abuse in a private outpatient treatment setting - psychiatric common grounds and typization of BDZ-bound addictive behaviour
10:00	S12-3 ROGER D. WEISS (Boston, MA, USA) - Opioid use disorder, depression, chronic pain, overdose, and suicidality: how are they related?
BREAK	
PLENARY LECTURES <i>Chair: José MARTINEZ-RAGA (Valencia, Spain, EU)</i> <i>Carlos Roncero (Salamanca, Spain, EU)</i>	
11:00	PL-10 YIFRAH KAMINER (Farmington, CT, USA) - Challenges for the Treatment of Co-occurring Depression in Youth with SUD: Highs and Lows
12:00	PL-11 DANIELE LA BARBERA (Palermo, Italy) - Behavioural Addictions and Dual Disorders
13:15	LUNCH BREAK

Plenary Room	ABSTRACT No	
PLENARY LECTURES		
<i>Chair: Lorenzo Somaini (Biella, Italy, EU)</i> <i>Maurice Dematteis (Grenoble, France, EU)</i>		
14:30	PL-12	JOSÈ MARTINEZ-RAGA (Valencia, Spain) - Causality or casuality. ADHD and substance use disorders
15:30	PL-13	GABRIELE FISCHER (Vienna, Austria) - Prisoners with substance use disorder and other comorbidities – medical and human rights considerations
PARALLEL SYMPOSIA		
Plenary Room	ABSTRACT No	13- NOVEL PSYCHOACTIVE SUBSTANCES: PSYCHIATRIC CONSEQUENCES AND RELATED BEHAVIOURAL ADDICTIONS IN DUAL DIAGNOSED PATIENTS <i>Chair: Rok Tavcar (Ljubljana, Slovenia, EU)</i>
16:30	S13-1	MOJCA ZVEZDANA DERNOVSEK (Ljubljana, Slovenia, EU) - Novel psychoactive substances use: challenges in assessing, diagnostic, treatment and clinical management in young forensic patients
17:00	S13-2	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel psychoactive synthetic cannabinoids and cathinones use: challenges in assessing, diagnostic, treatment and clinical management in dual disorders
17:30	S13-3	ROK TAVCAR (Ljubljana, Slovenia, EU) - Novel psychoactive substances use: challenges in assessing, diagnostic, treatment and clinical management of patients with schizophrenia
Room A		14- ARE WE ABLE TO DEVELOP APPROPRIATE DUAL DISORDERS TREATMENT RESOURCES?: BARRIERS AND FACILITATORS <i>Chair: Lola Peris (Neuchatel, Switzerland)</i>
16:30	S14-1	CELIA FRANCO (Coimbra, Portugal, EU) - Is the road to develop dual disorders treatment programs and resources long and winding?
17:00	S14-2	LARS LIEN (Oslo, Norway) - Do we know how to advance in the development of dual disorders treatment programs and resources?
17:30	S14-3	LOLA PERIS (Neuchatel, Switzerland) - Are dual disorders integrated treatment programs and resources a realistic issue today?
Room B		15-TOWARD A PSYCHOPATHOLOGY SPECIFIC TO SUDS. AN UP TO DATE <i>Chair: Angelo G.I. Maremmanni (Viareggio, Italy, EU)</i>
16:30	S15-1	IACOPO BELCARI (Pisa, Italy, EU) - Personality traits and aggressive behaviour of Dual Disorder Patients
17:00	S15-2	ICRO MAREMMANI (Pisa, Italy, EU) - Affective temperaments as preexisting addiction factors
17:30	S15-3	ANGELO G.I. MAREMMANI (Viareggio, Italy, EU) - Toward a psychopathology specific to SUDs. An up to date
PLENARY LECTURES		
<i>Chair: Icro Maremmanni (Pisa, Italy, EU)</i> <i>Pedro Ruiz (Houston, TX, USA)</i>		
18:00	PL-14	ARTURO G. LERNER (Netanya, Israel) - Hallucinogen persisting perception disorders: The story of “dragons, fairies and giants” or “witches do certainly exist” or “the never ending trip”
19:00		CLOSING CEREMONY

POSTER SESSION

PO-1. A. Adan et al. (Barcelona, Spain, EU) - Circadian Rhythms In Substance Use Disorders With And Without Depression
PO-2. A. Adan et al. (Barcelona, Spain, EU) - Neuropsychological profile of dual depressed patients
PO-3. T. Aladashvili (Tbilisi, Georgia) - Borderline personality disorder and comorbid addiction
PO-4. E. Albuquerque and T. Carvalhão (Coimbra, Portugal, EU) - Multiple sclerosis and cognitive decline, presenting with alcohol abuse and compulsive buying: A case report
PO-5. E. Atzori et al. (Roma, Italy, EU) - Evidence-based prevention of substance abuse in high school adolescents. The change of a perspective to protect and at the same time combat a stigma
PO-6. O. Austin and P. Rosca (Jerusalem, Israel) - Culture sensitivity in dual diagnosis services in Israel
PO-7. F. C. Blow et al. (Ann Arbor, MI, USA) - High risk drinking and prescription drug misuse: Relationship with suicidal ideation among US national guard soldiers
PO-8. M. Caloro et al. (Rome, Italy, EU) - Affective temperament in patients with persistent ADHD and substance use disorder (cocaine)
PO-9. T. Carvalhão and E. Albuquerque (Coimbra, Portugal, EU) - Behavioural dependencies: Pathological gambling - structured consultation experience in a central hospital in Portugal
PO-10. N. M. Casado-Espada et al. (Salamanca, Spain, EU) - Eating disorders and substance use in a sample of patients in the eating disorders treatment unity of Salamanca, Spain
PO-11. G. Catalano et al. (Roma, Italy, EU) - Towards a combined treatment for dual diagnosis
PO-12. L. Costantino (Roma, Italy, EU) - Psychopathology and clinic of eating disorders: The defence from depression. An interpretation according to Massimo Fagioli's "Human birth theory"
PO-13. P. Dannon (Tel Aviv, Israel) - Distinct response inhibition patterns in obsessive compulsive disorder patients and pathological gamblers
PO-14. J. I. de la Iglesia Larrad et al. (Salamanca, Spain, EU) - Cocaine-induced schizophrenia-like disorder: A case report
PO-15. A. Deschenau et al. (Villejuif, France, EU) - Acceptability of the assist questionnaire to assess substance use troubles in a French psychiatric patients' population
PO-16. A. Fiore and E. Vasile (Pordenone, Italy, EU) - Gratification in group psychotherapies of DD patients
PO-17. A. Fleischman (Tel Aviv, Israel) - Characteristics of patients with dual-diagnosis in outpatient addiction treatment services in Tel Aviv
PO-18. M. Fraga and P. Carriço (Coimbra, Portugal) - Perverse complicities
PO-19. A. Franceschini (Treviso, Italy, EU) - Misuse of prescription psychotropic drugs among women: A possible iatrogenic dual disorder?
PO-20. M. Á. García-Carretero et al. (Cadiz, Spain, EU) - The petit scale on schizophrenic population with alcohol use disorder: A pilot study
PO-21. A. Garcia-Guix et al. (Barcelona, Spain, EU) - Clinical profile of patients with dual disorders in an outpatient addiction centre follow up. An observational study
PO-22. M. Griffin (Belmont, MA, USA) - Grit in patients with substance use disorder

PO-23. B. Haight et al. (Richmond, VA, USA) - RBP-6000 Buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials
PO-24. M. Ilgen et al. (Stanford, CA, USA) - Randomised controlled trial of telephone monitoring with psychiatry inpatients with cooccurring substance use and mental health disorders
PO-25. M. Jesus et al. (Coimbra, Portugal, EU) - Alcohol consumption in the elderly
PO-26. S. Kandrakonda et al. (Hyderabad, India) - Comorbidity of Adult ADHD and Treatment-Resistant Depression: Augmentation with Methylphenidate
PO-27. A. Kantchelov and V. Parvanov (Sofia, Bulgaria, EU) - Enhancing treatment engagement in addicted patients with depression
PO-28. O. Kukhianidze and N. Okribelashvili (Tbilisi, Georgia) - Some issues in dual diagnosis in psychiatry in Georgia
PO-29. S. P. Kurtz et al. (Miami, FL, USA) - Brief interventions for young adults who use drugs: 'The moderating effects of resilience and trauma'
PO-30. M. Lucas et al. (Albacete, Spain, EU) - The difficulty of the psychopharmacological treatment in dual pathology
PO-31. C. Manni et al. (Pisa, Italy, EU) - From intense to occasional use of cocaine in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) patients treated with stimulant medications
PO-32. V. Marcinkene and A. Sangarijeva (Riga, Latvia, EU) - Impact of methadone long-term pharmacotherapy program on the results of HIV treatment in Latvia
PO-33. J. E. Marquez-Arrico et al. (Barcelona, Spain, EU) - Personality traits of patients with Dual Disorders: A psychobiological approach
PO-34. D. Medved et al. (Oslo, Norway) - Disease burden in ageing long-term opioid maintenance treatment patients; the triple burden
PO-35. F. Mora Mínguez et al. (Madrid, Spain, EU) - Excessive use of new technologies as a risk factor for eating disorders
PO-36. A. Neven (Den Haag, Netherlands) - The efficacy of IDDT on hospitalized dual disorder patients
PO-37. A. Neven (Den Haag, Netherlands) - Evaluation of seclusion in patients with severe dual disorders
PO-38. L. Oviedo et al. (Barcelona, Spain, EU) - Sociodemographic and clinical characteristics of methamphetamine shabu users in Barcelona
PO-39. A. Pallucchini et al. (Pisa, Italy, EU) - Clinical Characteristics of Dual Disorder (Adult ADHD with and without cocaine abuse) patients
PO-40. V. Perepjolkina et al. (Riga, Latvia, EU) - Pathological personality traits among patients with alcohol use disorder: Assessment of comorbidity of personality pathology and alcohol dependence
PO-41. L. Peris et al. (Neuchâtel, Switzerland) - Early abstinence, exercise and craving: A preliminary study
PO-42. R. M. Prado (Madrid, Spain, EU) - "Chemsex": How and why should we treat this patients in an addiction centre

PO-43. G. Prat et al. (Manresa, Spain, EU) - Factors related to brain impairment in dual schizophrenia
PO-44. S. Rabinovitz et al. (Haifa, Israel) - Substance use and severe mental health outcomes in sexual assault victims
PO-45. I. Ritacco (Roma, Italy, EU) - Alexithymia and benzodiazepine misuse
PO-46. M. Robles-Martínez et al. (Barcelona, Spain, EU) - Cannabis hyperemesis syndrome in a patient with generalized developmental disorder
PO-47. M. Robles Martínez et al. (Barcelona, Spain) - Erectile dysfunction secondary to repeated priapism due to chronic consumption of GHB
PO-48. P. Rocco (Castelfranco Veneto, Italy, EU) - ADHD in heroin addicts: Prevalence and psychiatric comorbidity
PO-49. P. Romero et al. (Albacete, Spain, EU) - Multidisciplinary approach for patients with dual pathology
PO-50. P. Rosca et al. (Jerusalem, Israel) - Rehabilitation in dual diagnosis: Filling the gap in the Israeli policy
PO-51. A. Ruz Sánchez et al. (Granada, Spain, EU) - A case of psychosis by Ayahuasca
PO-52. R. B. Sauras Quetcuti et al. (Barcelona, Spain) - First psychotic episodes in smoked methamphetamine users: Patterns of use and clinical features
PO-53. L. Shriki-Tal et al. (Ness-Ziona, Israel) - The new youth dual disorders day care clinic – system in progress
PO-54. G. Spinnato et al. (Palermo, Italy, EU) - Towards a nosography of “dual disorder”: Qualitative analysis of some clinical types
PO-55. R. G. Stern and J. E. Stern (Staten Island, NY, USA) - Trazodone for insomnia in patients with substance abuse - a critical review
PO-56. T. Stoykova (Sofia, Bulgaria, EU) - Addicted patients with personality disorders: Preconditions, challenges and psychotherapeutic mechanisms of change
PO-57. C. Tagliarini et al. (Pisa, Italy, EU) - Specific psychopathology of SUDs. Comparison between Italian and migrant patients
PO-58. A. Ulmer (Stuttgart, Germany, EU) - Addressing smoking three times a year
PO-59. A. Wolf et al. (Ness Ziona, Israel) - The new dual disorders division – system in progress: Past vs future

Faculty

Ana ADAN	Department of Clinical Psychology and Psychobiology, and Institute of Neurosciences, University of Barcelona, Spain, EU - [E-Mail: aadan@ub.edu]
Tamar ALADASHVILI	Centre for Mental Health and Prevention of Addiction, Tbilisi, Georgia - [E-Mail: aladashvilitamar@yahoo.com]
Rosa ALATI	University of Queensland QLD, Brisbane, Australia - [E-Mail: r.alati@sph.uq.edu.au]
Elisabete ALBUQUERQUE	Coimbra Hospital and University Centre, Coimbra, Portugal, EU - [E-Mail: a.didascal@gmail.com]
Emanuela ATZORI	Clinical Psychologist, Roma, Italy, EU - [E-Mail: emanuela.atzori@tin.it]
Ofra AUSTIN	Department for the Treatment of Substance Abuse, Ministry of Health, Israel, Jerusalem, Israel - [E-Mail: OFRA.AUSTIN@MOH.GOV.IL]
Iacopo BELCARI	VP Dole Research Group, Institute of Behavioural Sciences (IBS), Pisa, Italy, EU - [E-Mail: iacopo.belcari@gmail.com]
Amine BENYAMINA	Centre Enseignement, Recherche, Traitement des addictions, Hopitaux Universitaires Paris-Sud (AP-HP), Paris, France, EU - [E-Mail: amine.benyamina@pbr.aphp.fr]
Tony BLOEMENDAAL	Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands - [E-Mail: t.bloemendaal@fivoor.nl]
Annette BONEBAKKER	Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands, EU - [E-Mail: a.bonebakker@fivoor.nl]
Frederic C BLOW	Addiction Centre, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA - [E-Mail: fredblow@umich.edu]
Annette BONEBAKKER	Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands, EU - [E-Mail: a.bonebakker@fivoor.nl]
Nadir BOURBON	Department Psychiatry-Addiction. Psychiatric Hospital Frantz Fanon. Blida. Algeria - [E-Mail: n.bourbon@hotmail.com]
George BROUSSE	University Clermont Auvergne, Clermont Ferrand, France, EU - [E-Mail: gbrousse@chu-clermontferrand.fr, h.rahoui@ch-sainte-anne.fr]
Matteo CALORO	NESMOS department, University of Rome Sapienza, Medical School, Sant'Andrea Hospital, Rome, Italy, EU - [E-MAIL: m.caloro@gmail.com]
Teresa CARVALHÃO	Centro Hospitalar e Universitário de Coimbra - Psychiatry Department, Coimbra, Portugal, EU - [E-Mail: tecarvalhaosantos@gmail.com]
Nerea Maria CASADO-ESPADA	Salamanca University Healthcare Complex, - [E-Mail: nmcasado91@gmail.com]
Miguel CASAS	Universitat Autònoma del Barcelona, Spain, EU - [E-Mail: mcasas@vhebron.net]
Gabriella CATALANO	Drug Addiction Unit, USL Roma 1, Roma, Italy, EU - [E-Mail: gabriella.catalano@aslroma1.it]
Carlo Ignazio CATTANEO	Department of Mental Health Novara, Borgomanero, Italy, EU - [E-Mail: dr.carloignaziocattaneo@gmail.com]
Thomas CLAUSEN	Norwegian Centre for Addiction Research, University of Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]
Ludovica COSTANTINO	Psychiatrist and Psychotherapist, Roma, Italy, EU - [E-Mail: mm8508@mclink.it]
Pinhas DANNON	Tel Aviv University Ness Zionah Mental Health Ctr, Tel Aviv, Israel - [E-Mail: pinhas.danon@moh.gov.il]

Faculty

Javier Ignacio DE LA IGLESIA LARRAD	Salamanca Healthcare Complex,, Salamanca, Spain, EU - [E-Mail: javidelaiglesia@hotmail.com]
Mirjana DELIC	Centre for Treatment of Drug Addiction. University Psychiatric Clinic Ljubljana, Slovenia, EU - [E-Mail: mirjanadelic@yahoo.com]
Maurice DEMATTEIS	CHU Grenoble-Alpes, Grenoble, France, EU; INSERM UMR 987, Boulogne Billancourt, France; Hospital Cochin, Paris, France, EU -, Grenoble, France, EU - [E-Mail: MDematties@chu-grenoble.fr]
Mojca Zvezdana DERNOVSEK	Medical School University of Ljubljana, Slovenia, EU - [E-MAIL: mojca_dernovsek@t-2.net]
Alice DESCHENAU	Paul Guiraud Hospital, Villejuif, France, EU - [E-Mail: alice.deschenau@gh-paulguiraud.fr]
Daniel FEINGOLD	Ariel University, Ariel, Israel, - [E-Mail: d.y.feingold@gmail.com]
Carmen FERNANDEZ CACERES	Centros de Integración Juvenil A.C. (CIJ), Mexico City, Mexico, - [E-Mail: cfernandez@cij.gob.mx]
Andrea FIORE	AAS 5 Friuli Occidentale, Pordenone, Italy, EU - [E-Mail: fioreandrea.a@libero.it]
Gabriele FISCHER	Medical School, University of Vienna, Austria, - [E-Mail: gabriele.fischer@meduniwien.ac.at]
Anat FLEISCHMAN	Yaffo Community Mental Health Centre, Tel Aviv, Israel - [E-Mail: anat.fleischman@gmail.com]
Francina FONSECA	Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Manuela FRAGA	Equipa de Tratamento de Coimbra do Departamento de Intervenção em Comportamentos Aditivos e Toxicodepência, Coimbra, Portugal - [E-Mail: fraga.manuela@gmail.com]
Anna FRANCESCHINI	Addiction Medicine Clinic, NHS Treviso, Italy, EU - [E-Mail: anna.franceschini@aulss2.veneto.it]
Celia FRANCO	Coimbra University Hospital, Coimbra, Portugal, EU - [E-Mail: celiacfranco@gmail.com]
Andrea GALLEGOS-CARI	Institute for attention and prevention of addictions in Mexico City (IAPA), Mexico City, Mexico - [E-Mail: agallegosc@iapa.cdmx.gob.mx]
Miguel Ángel GARCÍA-CARRETERO	CTS-391 Multidisciplinary Group for the progress of Mental Health, Cadiz University; School of Nursing and Physiotherapy in Cadiz, Spain, EU - [E-Mail: miguel.garcia.carretero@hotmail.com]
Alexandra GARCIA-GUIX	Cas Santa Coloma, Institut de Neuropsiquiatria i addiccions-INAD, Parc de Salut Mar, Barcelona, Spain, EU - [E-Mail: 62755@parcdesalutmar.cat]
Margaret GRIFFIN	McLean Hospital/Harvard Medical School, Boston, MA, USA, Belmont, MA, USA - [E-Mail: mgriffin@mclean.harvard.edu]
Barbara HAIGHT	Indivior Inc., Richmond, VA, USA - [E-Mail: Barbara.R.Haight@gmail.com]
Liljana IGNJATOVA	Centre for Prevention and Treatment of Drug Use and Dependence. Psychiatric Hospital Skopje, Skopje, North Macedonia - [E-Mail: liljana.kitevaignjatova@yahoo.com]
Mark ILGEN	University of Michigan, VA Ann Arbor Healthcare System - [E-Mail: marki@umich.edu]

Faculty

Marjetka JELENC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: Marjetka.Jelenc@nijz.si]
Mariana JESUS	Department of Psychiatry, Coimbra Hospital and University Centre, Coimbra, Portugal, EU - [E-Mail: Mbsb.jesus@gmail.com]
Yifrah KAMINER	University of Connecticut School of Medicine, Connecticut, USA - [E-Mail: kaminer@uchc.edu]
Srinivas KANDRAKONDA	MaxCure Hospitals, Hi-tech City, , Hyderabad, India - [E-Mail: dr.srinivaskandrakonda@gmail.com]
Alexander KANTCHELOV	The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Andrej KASTELIC	University Psychiatric Hospital, Center for Treatment of Drug Addiction, Ljubljana, Slovenia, EU - [E-Mail: andrej.kastelic@psih-klinika.si]
Tatja KOSTNAPFEL	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: tatja.kostnapfel@nijz.si]
Reinhard Michael KRAUSZ	University of British Columbia, Vancouver, BC, Canada, - [E-Mail: M.Krausz@me.com]
Olga KUKHIANIDZE	Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia, Tbilisi, Georgia - [E-Mail: olga.kukhianidze@gmail.com]
Lee KUN-HUA	Yuli Hospital, Ministry of Health and Welfare; The Department of Educational psychology and Counseling, National Tsing Hua University, Taiwan, Hsinchu, Taiwan - [E-Mail: kunhualee627@gmail.com]
Steven P. KURTZ	ARSH Centre for Applied Research on Substance Use and Health Disparities, Abraham S. Fischler College of Education, School of Criminal Justice, Nova Southeastern University, Miami, FL, USA - [E-Mail: steven.kurtz@nova.edu]
Daniele LA BARBERA	University Hospital "Policlinico Paolo Giaccone", Palermo, Italy, EU - [E-Mail: daniele.labarbera@unipa.it]
Arturo LERNER	Department of Dual Disorders, Lev-Hasharon Centre, Netanya, Israel - [E-Mail: alerner@lev-hasharon.co.il]
Shaul LEV-RAN	Lev Hasharon Medical Centre, Netanya, Israel - [E-Mail: shauli.levran@gmail.com]
Lars LIEN	Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Oslo, Norway - [E-Mail: lars.lien@medisin.uoi.no]
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Marta LUCAS	Complejo Hospitalario Universitario de Albacete, Servicio de Salud Mental, Unidad de Hospitalización Breve,, Albacete, Spain, EU - [E-Mail: martamarta75@hotmail.com]
Mario MAJ	Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy, EU - [E-Mail: majmario@tin.it]
Corrado MANNI	School of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, EU - [E-Mail: corrado3@live.it]
Veronika MARCINKENE	Riga Stradins University, Riga, Latvia, EU - [E-Mail: ve.marcinkene@gmail.com]
Angelo G.I. MAREMMANI	Department of Psychiatry, Northern-West Tuscany Region Local Health Unit, Versilia Zone, Viareggio, Italy, EU - [E-Mail: angelogimaremmanni@gmail.com]

Faculty

Icro MAREMMANI	VP Dole Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmanni@med.unipi.it]
Rodrigo MARIN-NAVARRETTE	National Institute of Psychiatry 'Ramon de la Fuente', Mexico City, Mexico - [E-Mail: rmarin@inprf.gob.mx]
Julia E. MARQUEZ-ARRICO	University of Barcelona and Institute of Neuroscience, Barcelona, Spain, EU - [E-Mail: aadan@ub.edu]
José MARTINEZ-RAGA	Hospital Universitario Doctor Peset & Universitat de Valencia, Valencia, Spain, EU - [E-Mail: martinez_josrag@gva.es]
Vera MARTINS	Dual Pathology Unit, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, EU - [E-Mail: vera_martins_83@hotmail.com]
David MEDVED	Norwegian Centre for Addiction Research, Oslo, Norway - [E-Mail: david.medved@medisin.uio.no]
Fernando MORA MÍNGUEZ	Hospital Universitario Infanta Leonor Madrid, Spain, EU - [E-Mail: fernmora@gmail.com]
Ashley MULLER	Norwegian Centre for Addiction Research, University of Oslo, Norway - [E-Mail: ashley.muller@medisin.uio.no]
Filomena NETO	Community Mental Health Unit, Psychiatric Service, Centro Hospitalar Universitário de Coimbra, Portugal, Coimbra, Portugal, EU - [E-Mail: menaneto@gmail.com]
Arjen NEVEN	Fivoor, Den Haag, Netherlands - [E-Mail: a.neven@fivoor.nl]
Ernst NOORDRAVEN	Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands - [E-Mail: e.noordraven@fivoor.nl]
Lina OVIEDO	Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain, EU - [E-Mail: loviedo@parcdesalutmar.cat]
Matteo PACINI	Institute of Behavioural Sciences (IBS), Pisa, Italy, EU - [E-Mail: paciland@virgilio.it]
Alessandro PALLUCCHINI	School of Psychiatry, Department of Clinical and Experimental Psychiatry, University of Pisa, Pisa, Italy, EU - [E-Mail: pallucchini.a@gmail.com]
Myriam PAPERMAN	Hôpital Psychiatrique de Sainte Anne, Paris, France, EU - [E-Mail: myriampaperman@gmail.com]
Einat PELES	Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Israel - [E-Mail: einatp@tlvmc.gov.il]
Viktorija PEREPJOLKINA	Riga Stradiņš University, Riga, Latvia, EU - [E-Mail: viktorijaperepjolkina@gmail.com]
Lola PERIS	Neuchâtel Psychiatry Centre, Neuchâtel, Switzerland - [E-Mail: dolores.peris-diaz@cnp.ch]
Giulio PERUGI	Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Italy, EU - [E-Mail: giulio.perugi@med.unipi.it]
José Angel PRADO GARCIA	Centros de Integración Juvenil A.C. (CIJ), Mexico City, Mexico - [E-Mail: aprado@cij.gob.mx]
Rocio Molina PRADO	Instituto de Adicciones. Madrid Salud City Hall, Madrid, Spain, EU - [E-Mail: romopra1@hotmail.com]

Faculty

Gemma PRAT	University of Barcelona and Fundació Althaia, Manresa, Spain, EU - [E-Mail: gprat@althaia.cat, gprat@ub.edu]
Sharon RABINOVITZ	School of Criminology and The Unit for Excellence in Research & Study of Addiction (ERSA), The Centre for Rehabilitation Research, University of Haifa, Haifa, Israel - [E-Mail: sharonrs@univ.haifa.ac.il]
Ismail RAMMOUZ	Université Ibn Zohr, Faculté de Médecine, Agadir, Morocco - [E-Mail: ismailrammouzgmail.com]
Jeleana RISTIC-ILIC	Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, EU - [E-Mail: jelenaristicilic@gmail.com]
Ilario RITACCO	Roma, Italy, EU - [E-Mail: ritaccoilario@gmail.com]
María ROBLES-MARTÍNEZ	Instituto de Neuropsiquiatría y Adicciones (INAD). Parc de Salut Mar, Barcelona, Spain, - [E-Mail: correo@mariarobles.es]
Pasqualina ROCCO	Addiction Treatment Centre, Local Health Service n.2, Veneto, Castelfranco Veneto, Italy, EU - [E-Mail: pasqualina.rocco@aulss2.veneto.it]
Patricia ROMERO	Complejo Hospitalario Universitario de Albacete. Servicio de Salud Mental, Spain, EU, Albacete, Spain, EU - [E-Mail: patriciaromerorodenas@gmail.com]
Carlos RONCERO	Psychiatric Service, University of Salamanca Health Care Complex & Institute of Biomedicine of Salamanca, Psychiatric Department, University of Salamanca, Salamanca, Spain, EU - [E-Mail: croncero@saludcastillayleon.es]
Paula ROSCA	Department for the Treatment of Substance Abuse, Ministry of Health, Hebrew University, , Jerusalem, Israel. - [E-Mail: Paola.Roska@MOH.GOV.IL]
Pedro RUIZ	Baylor College of Medicine, Houston, Texas, USA - [E-Mail: pruiemd@outlook.com]
Ana RUZ SÁNCHEZ	University Hospital Virgen de las Nieves, Granada, Spain, EU - [E-Mail: jflogrono@gmail.com]
Caroline SALOM	University of Queensland QLD, Brisbane, Australia - [E-Mail: c.salom@uq.edu.au]
Anat SASON	Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre Tel Aviv, Israel - [E-Mail: anatsas@tlvmc.gov.il]
Rosa Blanca SAURAS QUETCUTI	Institut de Neuropsiquiatria i Addiccions (INAD); Parc de Salut Mar, IMIM (Hospital del Mar Medical Research Institute, Barcelona, Catalogna, Spain - [E-Mail: rsauras@parcdesalutmar.cat]
Shaul SCHREIBER	Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Israel - [E-Mail: shaulsch@tlvmc.gov.il]
Christian SCHUTZ	Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, Canada, - [E-Mail: christian.schutz@ubc.ca]
Nusa SEGREC	Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, & Medical Faculty, University of Ljubljana, Slovenia, EU - [E-Mail: nusasegrec@hotmail.com]
Liron SHRIKI-TAL	Ness-Ziona – Be'er Yaacov Mental Health Medical Centre, Ness-Ziona, Israel - [E-Mail: aweller11@gmail.com]
Tania SILVA	Community Mental Health Unit, Psychiatric Service, Centro Hospitalar Universitário de Coimbra, Portugal, EU, Coimbra, Portugal, EU - [E-Mail: aniavdasilva.md@gmail.com]

Faculty

Lorenzo SOMAINI	Addiction Medicine Clinic (SerT) Cossano, Biella, Italy, EU - [E-Mail: Lorenzo.Somaini@aslbi.piemonte.it]
Giampaolo SPINNATO	UOC Addiction Unit, NHS Local Unit Palermo, Italy, EU - [E-Mail: sert.pa2@asppalermo.org]
Robert G. STERN	Staten Island University Hospital, , Staten Island, NY, USA - [E-Mail: rgsternd@gmail.com]
Tsvetana STOYKOVA	The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: cvetipost@gmail.com]
Nestor SZERMAN	University Hospital Gregorio Marañon, Madrid, Spain, - [E-Mail: nszermanb@gmail.com]
Claudia TAGLIARINI	School of Psychiatry, University of Pisa, Pisa, Italy, EU - [E-Mail: claudiatagliarini8@gmail.com]
Lars TANUM	Norwegian Centre for Addiction Research, University of Oslo, Norway, Oslo, Norway - [E-Mail: Lars.Tanum@ahus.no]
Rok TAVCAR	University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: rok.tavcar@psih-klinika.si]
Marta TORRENS	Department of Psychiatry, Universitat Autònoma de Barcelona, Spain - [E-Mail: mtorrens@parcdesalutmar.cat]
Albrecht ULMER	Addiction Practitioner, Stuttgart, Germany, EU - [E-Mail: albrecht.ulmer@gmx.de]
Roger D. WEISS	Harvard Medical School, Boston, MA, USA; McLean Hospital,, Belmont, MA, USA - [E-Mail: rweiss@mclean.harvard.edu]
Aviva WOLF	Ness-Ziona–Be'er Yaacov Mental Health Care Centre, Ness Ziona, - [E-Mail: shirleykeisar@hotmail.com]
Daniele ZULLINO	Neuroscience Centre, Université de Genève, Geneve, Switzerland - [E-Mail: Daniele.Zullino@hcuge.ch, h.rahioui@ch-sainte-anne.fr]



WADDFlorence2018

World Association on Dual Disorders | Congress

“The 2nd World Association of Dual Disorders (WADD) Congress, Florence, Italy, 25/10/2018-27/10/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 20 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”




European Union of Medical Specialists
EACCME - European Accreditation Council for Continuing Medical Education
Institution of the UEMS
Rue de l'Industrie 24, B-1040, Brussels
T: +32 2 649 5164 | F: +32 2 640 37 30 | E: accreditation@uems.eu

Platinum sponsor



Bronze sponsor



FLORENCE

WADDFlorence2018
World Association on Dual Disorders | Congress